triple hormone receptor agonist retatrutide for obesity ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon agonist, in adults with or “overweight” retatrutide triple agonist phase 2

Weight (kg) and BMI (kg/m 2 ) were recorded prior to initiation and after 1216 weeks of treatment with GLP-1 receptor agonist

Compounded Medications are Prepared for Patient-Specific use Pursuant to an Individual Prescription, are not FDA-Approved, and should only be used under the Guidance of a Licensed Doctor

We use non-GMO ingredients

These effects likely stem from GLP-1s action on brain receptors involved in reward processing

Ascension Research and Analytics Search Login 0 Cart Search 0 Cart In stock $75.00 You save (%) Melanotan 2 is provided as a research material intended for laboratory and analytical applications

Yes, Found will contact your insurance company to gather information needed for your personal coverage report